Treatment of histoplasmosis with MK-991 (L-743,872)

Antimicrob Agents Chemother. 1998 Jan;42(1):151-3. doi: 10.1128/AAC.42.1.151.

Abstract

BALB/c nu/+ immunocompetent and athymic (nu/nu) mice were infected intravenously with yeast cells of Histoplasma capsulatum. Mice were either given water (controls) intraperitoneally (i.p.) or given MK-991 i.p. once daily or twice daily. Protection was measured as prolonged survival or reduction in tissue counts. MK-991 was protective in immunocompetent mice, prolonging survival and reducing counts in spleen and livers at a dose as low as 0.05 mg/kg of body weight/day. MK-991 was modestly effective in athymic mice at a higher dose, 5 mg/kg/day. These studies suggest that MK-991 may be appropriate for clinical development in histoplasmosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Antifungal Agents / therapeutic use*
  • Caspofungin
  • Disease Models, Animal
  • Echinocandins
  • Histoplasma / drug effects
  • Histoplasmosis / drug therapy*
  • Immunocompetence*
  • Lipopeptides
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Microbial Sensitivity Tests
  • Peptides*
  • Peptides, Cyclic*

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides
  • Peptides, Cyclic
  • Caspofungin